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ABSTRACT
Objective: The purpose of this study was to estimate the prevalence and risk factors for diabetic peripheral neuropathy, to evaluate the score of 
neuropathy, and to determine the effect of pharmacist intervention toward diabetic neuropathy (DN) patients at Gatot Soebroto Hospital, Jakarta, in 
2013.
Methods: An analytic research was conducted using cross-sectional approach to find out the effect of pharmacist intervention toward DN risk factors 
and prevalence. Toronto clinical scoring system was used to score the symptoms and physical examination results. Data about sociodemographic 
characters, age, duration of diabetic, blood glucose, blood pressure, cardiovascular diseases, lifestyle, body mass index (BMI), and smoking were 
collected. Pharmacist intervention was given to increase patient information about DN and its risks factors.
Results: There were 59 respondents involved in this study. It can be found that 15.3% respondents had mild diabetic peripheral neuropathy, 1.7% had 
moderate diabetic peripheral neuropathy, 1.7% had severe diabetic peripheral neuropathy, and as much as 81,4% respondents had no neuropathy. 
There was a correlation (but not statistically significant) between diabetic peripheral neuropathy and its’ risks factors such as ages, duration of 
diabetes, sex, cardiovascular disease (hypertension and cardiac disease), and lifestyle (smoking habit and BMI).
Conclusion: Pharmacist intervention showed an increase on the patient’s knowledge about DN and also a significant decrease on the patient’s blood 
glucose level (p˂0.05).
Keywords: Diabetic neuropathy, Pharmacist role, Prevalence, Score, Risk factors, Blood glucose.
INTRODUCTION
Diabetes mellitus (DM) is a metabolic disorder, which is characterized 
by hyperglycemia [1]. The prevalence keeps increasing with time. In 
1995, it was oleh 4.0%, and in 2015, it is predicted to reach a level 
of 5.4%. In 1995, there were around 135 million of diabetes mellitus 
cases, and in 2015, it is predicted to increase to 300 million of cases [2].
The 2012 report of patients’ data at the Internal Department of Gatot 
Soebroto Hospital, Jakarta, showed that diabetes mellitus ranked the 
first with 14.508 cases, followed by hypertension with 5.875 cases 
and dyspepsia syndrome with 1.008 cases. Diabetes mellitus is a 
chronic disease that needs continuous treatment and education for the 
patients to prevent acute complication and to reduce the risk of long-
term complication [3]. Long-term complication from diabetes includes 
retinopathy, which can lead to vision loss, nephropathy that leads to 
renal failure, peripheral neuropathy followed by the risks of foot ulcer, 
amputation, and charcot joins, as well as autonomous neuropathy 
that leads to disorders in the gastrointestinal and urogenital tracts, 
cardiovascular symptoms, and erectile dysfunction [1].
Diabetic neuropathy (DN) is the presence and/or signs of peripheral 
nervous dysfunctions in patients with diabetes after the exclusion of 
other causes. About 60-70% of diabetic patients suffer from moderate 
to severe nervous system damage [4]. Diabetic peripheral neuropathy 
occurs in 50% of diabetic patients [5]. Duration of the disease is one 
of the factors that lead to increasing morbidity and mortality rates [6]. 
The prevalence of DN is 11.1% in the population at the age of 23-40 
ages. It increased to 32.3 years in the patients at the age of 60-80 years. 
When it comes to duration, 14.1% of the patients who had diabetes 
for <5 years developed neuropathy and 29.2% of diabetic patients 
who have diabetes for 9-11 years developed neuropathy [7]. Another 
research even found that 73.9% of the patients who had diabetes for 
<5 years had neuropathy and 100% of the patients who have diabetes 
for >15 years had neuropathy [8]. Almost 30% of the diabetic patients at 
the age of 40 years or more had sensational impairment on legs, which 
is the severest form of DN and the main contributor for amputation. 
More than 60% of non-traumatic amputations occurred in diabetic 
patients [4]. Patients with diabetes mellitus and peripheral neuropathy 
were at increased risk for developing tissue damage, which was 
followed by diabetic feet, diabetic ulcers, and even foot amputation [9]. 
These situations are the major causes of morbidity and mortality. The 
incidence rate can be reduced when the peripheral neuropathy can be 
detected at the earliest stadium possible [5].
Risk factors for diabetic peripheral neuropathy include improper blood 
sugar control, duration of the disease, hyperlipidemia, elevated albumin 
excretion, smoking habit, alcohol, low economic status, renal failure, 
and increased body mass index (BMI). Diabetic peripheral neuropathy 
is frequently associated with cardiovascular diseases, mortality, and 
microangiopathy [5,10-12].
The examination is necessary to prevent and treat nerve damage as the 
first step in identifying the symptoms in the sensor and motor systems, 
which are caused by the DN, after the exclusion of other causes. Clinical 
evaluation includes foot examination for foot pain, numbness, tingling, 
weakness and ataxia, and upper limb, examination for sensory system, 
which includes pinprick, temperature, light touch, vibration, and 
position sense, and examinations for Achilles reflex, and Patella reflex 
using reflex hammer [13].
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Gatot Soebroto Hospital is a military hospital located in Central Jakarta. 
It is a Type I hospital that deals with many diabetes mellitus cases. It 
even ranked the first of all diseases at the Internal Department of Gatot 
Soebroto Hospital, Jakarta. It was estimated that in 2012, 11-12% 
of 14.508 patients were diabetes mellitus cases and it is equaled to 
145 cases each month. Screening and treatment, which had been given 
for DN were limited to patients who had nervous impairment, while 
education provided by the pharmacists was in adequate, because of the 
limited number of staffs. Based on the elaboration above, a research 
is necessary to find out the prevalence of DN and risks factors for 
the diabetic patients to be judged as having DN. It is measured using 
Toronto clinical scoring system (TCSS) and in-depth interview to 
identify other diseases that may be developed by the patients, including 
cardiovascular diseases (coronary arterial diseases, triglycerides, 
and hypertension) and lifestyles, such as smoking habit. Then, the 
pharmacists provide education for the patients. The education includes 
providing valid information on the preventive measures, management, 
and proper regimen in the patients with DN. Therefore, some questions 
related to this research include the following:
1. What is the prevalence of DN at Gatot Soebroto Hospital?
2. What are the risk factors of DN?
3. What are the score of neuropathy in patients involved in this study?
4. What is the effect of pharmacist intervention toward DN patients at 
Gatot Soebroto Hospital, Jakarta, in 2013.
Based on the questions above, a research on “The Role of Pharmacists in 
Evaluating and Intervening the Patients with DN” was conducted.
METHODS
Materials
DN patients, medical records, and TCSS.
Methodology
An analytic research was conducted using cross-sectional approach to 
find out the prevalence of DN and risk factors. Data on the risk factors 
were collected from medical records of the patients and in-depth 
interviews (questionnaire). The tool used to determine the level of 
neuropathy was TCSS. Education was provided by the pharmacists by 
distributing brochures or providing information directly to the samples 
on the certain type of complication from diabetes mellitus, namely 
DN. The research involved qualitative (descriptive) and quantitative 
analyses using the statistical program.
Locus and time
The research was conducted in October 2013, at the outpatient room 
of endocrine metabolic internal polyclinic, Gatot Soebroto Hospital, 
Jakarta.
Population
Type 2 diabetes outpatient who visited the Endocrine Department/
Metabolic Internal Clinic at Gatot Soebroto Hospital, Jakarta, every 
month and met the inclusion criteria.
Respondents and number of respondents
Respondents of the research were patients with Type 2 diabetes 
mellitus that met the inclusion criteria. 59 patients served as the 
respondents for the research.
Determination of respondents
The respondents were selected using nonrandomize incidental 
sampling technique with prospective data collection.
Research stages
1. Selection of patients with Type 2 diabetes mellitus that met 
the inclusion criteria and had outpatient services at Endocrine 
Department/Metabolic Internal Clinic at Gatot Soebroto Hospital, 
Jakarta.
 Inclusion criteria: All of the patients with Type 2 diabetes mellitus 
at the outpatient room of Gatot Soebroto Hospital, Jakarta, age of 
>50 years, duration of diabetes for >5 years, and willingness to 
participate in the research by filling up informed consent.
 Exclusion criteria: Diabetic patients at the age of <50 years, duration 
of diabetes <5 years, patients with Type 2 diabetes mellitus with 
rheumatic, vitamin B12 deficiency, hypothyroidism, and drug abuse.
2. Filling up informed consent. The patients were given an explanation 
on the procedure, objective, and benefits of the research before filling 
up the informed consent.
3. Recording of complete identity of the patients in the data collection 
sheet, which included a number of medical record, name, age, and 
sex.
4. Recording of physical examination results (height, weight, blood 
pressure, and total cholesterol level) and laboratory examination 
from the medical record.
5. In-depth interviews to explore the risk factors for DN (blood glucose, 
hypertension, cholesterol, duration of diabetes, and smoking habit).
6. Examination by the physician for sensory function, motor function, 
and reflexes using TCSS. The examinations included:
Examinations for the symptoms:
 a.  Interview on the neuropathic symptoms on lower and upper 
extremities: Pain, numbness, tingling, and weakness
 b.  Examination for ataxia (movement coordination)
Examinations for reflexes:
 a. Examination for patella reflex on both feet
 b. Examination for Achilles reflex on both feet.
Sensory examination:
 a.  Sensory examination that included pinprick using lancet 
needle
 b.  Examination of temperature using hot water at a temperature 
of 40-50°C and 10-20°C
 c.  Examination of slow touch using cotton
 d.  Examination of vibration using a 128-Hz tuning fork
 e. Examination of position sense by passive moving of the toes
 f. Evaluation of TCSS
 g.  Education by the pharmacists. Before the education, the 
patients were given questionnaire on DN, followed by 
education session by providing brochures and information 
on the DN.
RESULTS
Sample of the research was 68 patients, who visited for outpatient 
services Endocrine Department/Metabolic Internal Clinic at Gatot 
Soebroto Hospital, Jakarta. During the research course, 9 patients 
dropped out because of failure to visit every month. Therefore, 
59 patients were used as sample. The research was conducted for 
3 months and 3 sessions of education were given to the patients with 
an interval of 1 month between the educations. Demographic data on 
the patient characteristic can be seen on Table 1.
The total populations involved in the research were 59 respondents that 
consisted of the following: 35.6% of the respondents aged 50-59 years, 
32.2% aged 60-69 years, and 32.3% age 70-80 years. Based on the 
gender, 44.1% of the respondents were male and the remaining 55.9% 
were female. Based on duration of the disease, 54.2% had been exposed 
to diabetes mellitus for 5-9 years, 33.9% for 10-19 years, 8.8% for 
20-29 years, and 3.4% for >30 years. Based on smoking habit, 28.6% 
of the respondents were smoking and 81.4% were not. Most of the 
respondents had normal body weight (67.8%) with 28.8% overweight 
and 3.4% obese; 54.2% of the respondents had hypertension and 
normal 45,8% were normotensive; 55,9% of the respondents had high 
cholesterol level and 44.1% had a normal level. Finally, 11.9% of the 
respondents had heart disease and 88.1% did not.
Table 2 shows that 81.4% of the respondents had no neuropathy, 15.3% 
had mild neuropathy, 1.7% had moderate neuropathy, and 1.7% had 
severe neuropathy.
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Table 3 showed the relationship between neuropathy and risk factors. 
It can be seen that the relationship between dependent variables of 
neuropathy and independent variable, namely DN, could be significant, 
with the Confidence Interval of p<0.05. However, when P value is 
more than 0.05, it means that there is no significant relationship 
between neuropathy and the independent variables. Table 3 shows that 
significance values of the dependent variables of neuropathy were all 
>0.05. However, there is still a correlation between the incidence of DN 
at Gatot Soebroto Hospital, Jakarta, with the risk factors for DN, namely, 
age, sex, duration of diabetes mellitus, blood glucose, hypertension, 
heart disease, cholesterol, smoking habit, and BMI.
From Table 4, it can be seen that the percent knowledge of the 
respondents with DN before the intervention was 54.5%, compared to 
that of 68.2% after the first intervention, and 90.9% after the second 
intervention. Meanwhile, knowledge of samples without neuropathy 
was 61.5% before the intervention, 64.6% after the first intervention, 
and 90.6% after the second intervention. In this case, it was found that 
knowledge of the respondents with and without DN increased after the 
first and the second intervention.
The research also found that 72.7% of the DN respondents had 
knowledge on the signs and symptoms of DN before the intervention, 
and it increased to 86.4% after the first intervention and 86.4% after the 
second intervention. On the other hand, 79.2% of the samples without 
neuropathy had knowledge on the signs and symptoms of DN before 
the intervention and it increased to 86.5% after the first intervention 
and 92.7% after the second intervention.
DISCUSSION
The major morbidity caused in the diabetic patients is due to dysfunction 
of several organ systems after a few years of having diabetes. Research 
has now clearly proved that these organ dysfunctions have their roots 
in diabetic pathophysiology. Many components of this pathophysiology 
have been identified. These components work interdependently with 
each other. One of the important factors identified is inflammation, 
which embraces the mechanisms such as oxidative stress, 
neovascularization, apoptosis, and cellular proliferation. It has been 
shown that inflammation plays an important role in microvascular as 
well as macrovascular complications of diabetes [14].
Neuropathy is the most common complication in diabetic patients.3 
Even though the estimated prevalence of DN varied greatly depending 
on the diagnostic criteria, at least 50% of diabetic patients had 
neuropathy and 30-50% of prediabetic patients had neuropathy. The 
severity of DN is related to duration of the disease and blood glucose 
level. In a study conducted in the patients who had been diagnosed 
with diabetes mellitus for 25 years, 12% of the patients had DN and the 
incidence increased to more than 50% after 25 years. An evaluation on 
6.487 diabetic patients was conducted in the United Kingdom and it was 
found that 5% of the patient’s age 20-29 years had DN and it increased 
to 44.2% in the patients at the age group of 70-79 years. Similarly, a 
report showed that 33% of patients at the age group of 18-70 years had 
DN and it increased to more than 50% in the elderly group [6].
One of the complications from diabetes mellitus is nervous damage, 
which is called DN. Its signs include foot pain. The characteristics 
of neuropathy on the feet include burning sensation and pinprick, 
numbness, tingling, weakness, ataxia (movement coordination) in 
addition to decreased reflex, and sensory system. Sensory nerve 
damage may lead to inability to perceive pain, heat, coldness, and or 
soft touch. Early examination is essential to prevent and treat the nerve 
damage. The first phase may include finding out sensory and motor 
symptoms caused by diabetes mellitus. Clinical evaluation includes an 
examination of feet, Achilles reflex, and Patella reflex using a tuning fork 
or biothesiometer [15].
TCSS was used to score the symptoms and physical examination 
results. This system is a simple method to evaluate DN. Easy to use 
and acceptable by the patient, the tool can be used to classify the 
severity level and correlated with the clinical changes associated with 
the development of DN. Each patient was asked about the existence of 
pain sensation (characteristics of neuropathic pain), such as burning 
and pricked sensation, numbness, tingling, and weakness on the feet. 
Sensory examination was conducted for feet first and given “normal” or 
“abnormal” value [16-19].
The examinations include (1) symptoms, foot symptoms (foot pain), 
numbness, tingling, weakness, ataxia, and upper limp symptoms. Each 
examination was given a score; 0=no symptom, 1=the symptoms existed, 
and with maximum score of 6, (2) examination of reflex was conducted 
on both feet for patella and Achilles reflexes; 2=no reflex, 0=normal 
reflex, with maximum total score of 8, (3) sensory examination included 
pinprick, temperature, light touch, vibration, and position sense; 
Table 1: Demographic characteristics of the patients
Variables Group Sample (%)
Age (years) 50-59 21 (35.6)
60-69 19 (32.2)
70-80 19 (32.2)
Sex Male 26 (44.1)
Female 33 (55.9)




Blood glucose Normal/controlled 26 (44.1)
No 33 (55.9)
Hypertension High blood pressure 32 (54.2)
Normotension 27 (45.8)
Cholesterol High total cholesterol 33 (55.9)
Normal total cholesterol 26 (44.1)
Heart disease Yes 7 (11.9)
No 52 (88.1)
Smoking Yes 11 (18.6)
No 48 (81.4)
Body mass index Normal 40 (67.8)
Over weight 17 (28.8)
Obese 2 (3.4)
DM: Diabetes mellitus
Table 2: Classification of the patients based on neuropathic 
scores
Neuropathy Score Samples (%)
No neuropathy 0-5 48 (81.4)
Mild neuropathy 6-8 9 (15.3)
Moderate neuropathy 9-11 1 (1.7)
Severe neuropathy ≥12 1 (1.7)
Total samples 59 (100)












Body mass index 0.765
DM: Diabetes mellitus
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1=abnormal, 0=normal, and with maximum total score of 19. Based 
on the neuropathic scores, the patients were classified as, (1) having 
no neuropathy with a score of 0-5, (2) having mild neuropathy with a 
score of 6-8, (3) having moderate neuropathy with a score of 9-11, and 
(4) having severe neuropathy with a score of ≥12 [16-19].
In this study, education was given to all of the respondents, both with and 
without DN, with the aim of improving their knowledge and motivation. 
The education included healthy behavioral promotion to obtain an 
optimum outcome. During the education sessions, the respondents 
were provided with brochures that contained information on DN and its 
aspects, including the healthy life behavior. The materials included, (1) 
healthy eating pattern, (2) the importance of physical exercises, (3) the 
use of diabetic treatment and drugs for certain situations in a safe and 
regular way, (4) self-monitoring of glucose level, and (5) routine foot 
care. The recommended actions to do by the patients included (1) not 
to walk on bare foot, including on the sand and water, (2) doing foot 
examination every day and reporting it to the physician when redness, 
wound, and scaling are identified, (3) making sure that there is no 
foreign object on the sandals or shoes, (4) always maintaining the feet 
in clean and dry condition as well as applying moisturizing on the dry 
feet, (5) regular nail trimming, (6) wearing comfortable socks, (7) make 
sure that the shoes are not too tight, too loose, or too high, and (8) no to 
use pillow or a bottle containing hot water or stone for the feet.
There are many risk factors for DN found in this study. The risk factor of 
age is correlated with blood clotting. There are two factors, which cause 
blood clotting, namely intrinsic and extrinsic factors. Both factors unite 
to activate prothrombin to thrombin. Intracellular hyperglycemia leads 
to the formation of advanced glycation end-product (AGEs). The process 
originally forms reversible glycation; sustained hyperglycemia will lead 
to irreversible process that will contribute to the increase of AGEs level 
in the patients with diabetes mellitus. The AGEs inhibit the production 
of prostacyclin and induce plasminogen activator inhibitor-1 because 
of thrombocyte aggregation and fibrin stabilization that facilitate the 
thrombocytes, microthrombus activated by AGEs, to cause local hypoxia 
and microangiopathy, and eventually to neuropathy [6]. The risk 
factors for DN include uncontrolled blood glucose, duration of diabetes 
mellitus, and cardiovascular diseases (hyperlipidemia, hypertension, 
smoking, and increased BMI) [5]. Chronic hyperglycemia in the patients 
with diabetes mellitus leads to endothelial dysfunction, due to the 
increase in AGEs pathway, polyol pathway, free radicals, and protein 
kinase C pathway. Endothelial dysfunction will lead to microangiopathy 
and nerve hypoxia, and eventually lead to the irreversible damage of 
nerve structure. Risk factors of endothelial dysfunction include chronic 
hyperglycemia, elevated fat levels, high blood pressure, elevated BMI, 
and smoking habit [5].
In this study, many respondents did not have DN since they attempted 
to improve their knowledge and applied it on their health, compared 
to those who had DN. It was possible that they had the DN earlier 
that they had the knowledge since they did not pay attention to the 
risk factors of DN. Age is another risk factor for the patients with 
diabetes mellitus to have neuropathy. The research found that 82% of 
the respondents had knowledge on the age as a risk factor before the 
intervention; it remained 82% after the first intervention and after the 
second intervention. In the samples without neuropathy, 68.8% of the 
respondents provided a correct answer; it increased to 70.8% after the 
first intervention and 81.3% after the second intervention. This shows 
that the respondent did not have neuropathy because they attempted 
to improve their knowledge and applied it on their health, compared to 
those without neuropathy.
When it comes to knowledge about the treatment for DN, 18% of the 
respondents with neuropathy provided correct answer before the 
intervention; it increased to 36.4% after the first intervention and 
decreased to 27.3% after the second intervention. In the samples 
without DN, 31.3% provided correct answer before the intervention; it 
increased to 45.8% after the first intervention and decreased to 35.4% 
after the second intervention. This shows a similar character in that 
respondents without neuropathy had improving knowledge after each 
intervention compared to those with DN.
For the risk factor of lifestyle, 77.3% of the respondents with DN provided 
correct answer before the intervention; it increased 79.5% after the first 
intervention and remained 79% after the second intervention. In the 
samples without DN, 83% of the respondents provided correct answer; 
it increased to 84.4% after the first intervention and 87.5% after the 
second intervention. In line with the study conducted by Suppapitiporn 
et al., a good outcome was obtained from the patients who received 
counseling, compared to those who did not [19].
CONCLUSION
Based on the research, it can be concluded that from the 59 patients 
involved in this study, 17.6% had DN and the remaining 81.4% did not. 
Blood glucose, age, duration of disease, hypertension, heart disease, 
obesity, high cholesterol level, and elevated BMI are some of the risks 
factors for DN in the patients with diabetes mellitus. Pharmacist 
intervention showed an increase on the patient’s knowledge about 
DN and also a significant decrease on the patient’s blood glucose level 
(p˂0.05).
REFERENCES
1. American Diabetes Association. Diagnosis and classification of 
diabetes mellitus. Diabetes Care 2012;35 Suppl 1:S64-71.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 
1995-2025: Prevalence, numerical estimates, and projections. Diabetes 
Care 1998;21(9):1414-31.
3. American Diabetes Association. Standards of medical care in diabetes 
2013. Diabetes Care 2013;36 Suppl 1:S11-66.
4. National Diabetes Information Clearinghouse. National Diabetes 
Statistics, 2011. National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK); 2011.
5. Tesfaye S. Epidemiology and etiology of diabetic peripheral 
neuropathies. Adv Stud Med 2004;4(10G):S1014-21.
6. Feldman EL, Vincent A. Review the prevalence, impact, and 
multifactorial pathogenesis of diabetic peripheral neuropathy. Adv Stud 
Med 2004;4(8A):S642-9.
7. Morkrid K. The Prevalence of and Risk Factors for Diabetic Peripheral 
Neuropathy Among Type 2 Diabetic Outpatients in Bangladesh. 
Table 4: Sample distribution based on the questionnaire answer
Number of samples with correct answer
Points of question Neuropathy No neuropathy
SI (%) I1 (%) I2 (%) SI (%) I1 (%) I2 (%)
General knowledge on diabetic neuropathy 6 (54.5) 7 (68.2) 10 (90.9) 29 (61.5) 31 (64.6) 44 (90.6)
Signs and symptoms of diabetic neuropathy 8 (72.7) 9 (86.4) 9 (86.4) 38 (79.2) 41 (86.5) 45 (92.7)
Age is a risk factor for diabetic neuropathy 9 (82.0) 9 (81.8) 9 (81.8) 33 (68.8) 34 (70.8) 39 (81.3)
Treatment for diabetic neuropathy 2 (18.2) 4 (36.4) 3 (27.3) 15 (31.3) 22 (45.8) 17 (35.4)
Lifestyle of patients with DM 8 (77.3) 9 (79.5) 8 (77.3) 40 (82.8) 41 (84.4) 42 (87.5)
Mean±standard deviation 6.6±2.8 7.6±2.2 7.8±2.8 31±9.9 33.8±7.9 37.4±11.6
SI: Before Intervention, I1: Intervention 1, I2: Intervention 2, Number of samples=59 patients, DM: Diabetes mellitus
131
Asian J Pharm Clin Res, Vol 10, Issue 2, 2017, 127-131
 Keban et al. 
University of Oslo, Faculty of Medicine, Norway. 2007. Available 
from: https://www.duo.uio.no/bitstream/handle/10852/30151/69091.
pdf? sequence=1. [Last accessed on 2016 Jan 08].
8. Oguejiofor OC, Odenigbo CU, Oguejiofor CB. Evaluation of the effect 
of duration of diabetes mellitus on peripheral neuropathy using the 
United Kingdom screening test scoring system, bio-thessiometry and 
aesthesiometry. Niger J Clin Pract 2007;13(3):240-7.
9. Cornblath DR. Diabetic neuropathy - diagnostic methods. Adv Stud 
Med 2004;4:8A.
10. Bril V, Perkins B, Toth C. Neuropathy: Clinical practice guidelines 
expert committee. Can J Diabetes 2013;37:S142-4.
11. Canadian Diabetes Association. Clinical practice guidelines for the 
prevention and management of diabetes in Canada. Can J Diabetes 
2008;32 Suppl 1:S140-41, S199-201.
12. De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on 
chronic microvascular complications in Type 1 diabetic patients. 
Diabetes Care 2005;28(7):1649-55.
13. Feldman EL. Etiology of diabetic microvascular disease and scientific 
rationale for new therapeutic targets. Adv Stud Med 2005;5(3A):S138-43.
14. Navale AM, Paranjape AN. Role of inflammation in development of 
diabetic complications and commonly used inflammatory markers 
with respect to diabetic complications. Int J Pharm Pharm Sci 
2013;5 Suppl 2:1-15.
15. Rampello L, Vecchio I, Malaguarnera G. Diabetic neuropathy diagnosis. 
Acta Med Mediterr 2012;28:133-8.
16. Bril V, Perkins BA. Validation of the Toronto clinical scoring system for 
diabetic polyneuropathy. Diabetes Care 2002;25(11):2048-52.
17. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, 
Baconja M, et al. Painful diabetic peripheral neuropathy: Consensus 
recomendations on diagnosis, assesment and management. Diabetes 
Metab Res Rev 2011;27(7):629-38.
18. Bril V, Tomioka S, Buchanan RA, Perkins BA. Complications reliability 
and validity of the modified Toronto clinical neuropathy score in 
diabetic sensorimotor polyneuropathy. Diabet Med 2009;26(3):240-6.
19. Suppapitiporn S, Chindavijak B, Onsanit S. Effect of diabetes drug 
counseling by pharmacist, diabetic disease booklet and special medication 
containers on glycemic control of Type 2 diabetes mellitus: A randomized 
controlled trial. J Med Assoc Thai 2005;88 Suppl 4:S134-41.
